Literature DB >> 30154021

A population-based study of treated mental health and persistent pain conditions after transport injury.

Melita J Giummarra1, Oliver Black2, Peter Smith3, Alex Collie4, Behrooz Hassani-Mahmooei4, Carolyn A Arnold5, Jennifer Gong2, Belinda J Gabbe6.   

Abstract

BACKGROUND: Persistent pain and mental health conditions often co-occur after injury, cause enormous disability, reduce social and economic participation, and increase long-term healthcare costs. This study aimed to characterise the incidence, profile and healthcare cost implications for people who have a treated mental health condition, persistent pain, or both conditions, after compensable transport injury.
METHODS: The study comprised a population cohort of people who sustained a transport injury (n = 74,217) between 2008 to 2013 and had an accepted claim in the no-fault transport compensation system in Victoria, Australia. Data included demographic and injury characteristics, and payments for treatment and income replacement from the Compensation Research Database. Treated conditions were identified from 3 to 24-months postinjury using payment-based criteria developed with clinical and compensation system experts. Criteria included medications for pain, anxiety, depression or psychosis, and services from physiotherapists, psychologists, psychiatrists, and pain specialists. The data were analysed with Cox Proportional Hazards regression to examine rates of treated conditions, and general linear regression to estimate 24 month healthcare costs.
RESULTS: Overall, the incidence of treated mental health conditions (n = 2459, 3.3%) and persistent pain (n = 4708, 6.3%) was low, but rates were higher in those who were female, middle aged (35-64 years), living in metropolitan areas or neighbourhoods with high socioeconomic disadvantage, and for people who had a more severe injury. Healthcare costs totalled more than $A707 M, and people with one or both conditions (7.7%) had healthcare costs up to 7-fold higher (adjusting for demographic and injury characteristics) in the first 24 months postinjury than those with neither condition.
CONCLUSIONS: The incidence of treated mental health and persistent pain conditions was low, but the total healthcare costs for people with treated conditions were markedly higher than for people without either treated condition. While linkage with other public records of treatment was not possible, the true incidence of treated conditions is likely to be even higher than that found in this study. The present findings can be used to prioritise the implementation of timely access to treatment to prevent or attenuate the severity of pain and mental health conditions after transport injury.
Copyright © 2018 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Crash; Health service use; Motor vehicle collision; Transport injury

Mesh:

Substances:

Year:  2018        PMID: 30154021     DOI: 10.1016/j.injury.2018.08.008

Source DB:  PubMed          Journal:  Injury        ISSN: 0020-1383            Impact factor:   2.586


  3 in total

1.  Different Patterns of Mental Health Outcomes among Road Traffic Crash Survivors: A Prospective Cohort Study.

Authors:  Jelena Kovacevic; Ivica Fotez; Ivan Miskulin; Davor Lesic; Maja Miskulin; Terezija Berlancic; Ivan Vukoja; Slavko Candrlic; Hrvoje Palenkic; Marija Candrlic
Journal:  Int J Environ Res Public Health       Date:  2021-02-07       Impact factor: 3.390

2.  Predictors of Mental Health Outcomes in Road Traffic Accident Survivors.

Authors:  Jelena Kovacevic; Maja Miskulin; Dunja Degmecic; Aleksandar Vcev; Dinko Leovic; Vladimir Sisljagic; Ivana Simic; Hrvoje Palenkic; Ivan Vcev; Ivan Miskulin
Journal:  J Clin Med       Date:  2020-01-22       Impact factor: 4.241

3.  Comparison of physical and psychological health outcomes for motorcyclists and other road users after land transport crashes: an inception cohort study.

Authors:  Lisa N Sharwood; Annette Kifley; Ashley Craig; Bamini Gopinath; Jagnoor Jagnoor; Ian D Cameron
Journal:  BMC Public Health       Date:  2021-11-02       Impact factor: 3.295

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.